UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020658
Receipt number R000023845
Scientific Title Study on the effect of tadalafil on bladder blood flow in patients with lower urinary tract symptoms due to benign prostatic hyperplasia
Date of disclosure of the study information 2016/02/01
Last modified on 2019/01/22 11:39:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study on the effect of tadalafil on bladder blood flow in patients with lower urinary tract symptoms due to benign prostatic hyperplasia

Acronym

Effect of tadalafil on bladder blood flow in benign prostatic hyperplasia

Scientific Title

Study on the effect of tadalafil on bladder blood flow in patients with lower urinary tract symptoms due to benign prostatic hyperplasia

Scientific Title:Acronym

Effect of tadalafil on bladder blood flow in benign prostatic hyperplasia

Region

Japan


Condition

Condition

Patients with lower urinary tract symptoms due to benign prostatic hyperplasia

Classification by specialty

Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The effect of tadalafil on bladder blood flow

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Change in resistive index of vesical artery on doppler ultrasound at 8 weeks after tadalafil administration

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administration of tadalafil 5mg once per day for 8 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit

75 years-old >

Gender

Male

Key inclusion criteria

I-PSS 13 or more, prostate volume 20ml or more, Qmax on uroflowmetry between 4 ml/sec and 15 ml/sec

Key exclusion criteria

postvoid residual urine 150 ml or more, uncontrolled diabetes mellitus, patients taking medication for lower urinary tract symptoms, patients who underwent surgery or radiation to the prostate

Target sample size

22


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hidehiro Kakizaki

Organization

Asahikawa Medical University

Division name

Department of Renal and Urologic Surgery

Zip code


Address

2-1-1-1 Midorigaoka-Higashi, Asahikawa, Japan

TEL

0166-68-2533

Email

kaki@asahikawa-med.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hidehiro Kakizaki

Organization

Asahikawa Medical University

Division name

Department of Renal and Urologic Surgery

Zip code


Address

2-1-1-1 Midorigaoka-Higashi, Asahikawa, Japan

TEL

0166-68-2533

Homepage URL


Email

kaki@asahikawa-med.ac.jp


Sponsor or person

Institute

Hidehiro Kakizaki

Institute

Department

Personal name



Funding Source

Organization

Asahikawa Medical University, Department of Renal and Urologic Surgery

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

旭川医科大学病院


Other administrative information

Date of disclosure of the study information

2016 Year 02 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2016 Year 01 Month 20 Day

Date of IRB


Anticipated trial start date

2016 Year 02 Month 01 Day

Last follow-up date

2019 Year 01 Month 20 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 01 Month 20 Day

Last modified on

2019 Year 01 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023845


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name